Business Context and Reporting Period
Company: eXoZymes Inc. (formerly Invizyne Technologies, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: eXoZymes is a pre-revenue, development-stage biotechnology company focused on "cell-free" biomanufacturing using AI-designed enzymes ("exozymes"). The company aims to produce high-value chemicals (nutraceuticals, pharmaceuticals, biofuels) more sustainably and scalably than traditional petrochemical or cell-based synthetic biology methods. The company completed its Initial Public Offering (IPO) on November 11, 2024, and rebranded from Invizyne Technologies in February 2025.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $70,069 |
| Net Loss | $(5,861,335) | $(2,038,389) |
| Operating Costs | $5,932,105 | $1,866,291 |
| Research & Development (Net of Grants) | $1,868,766 | $527,480 |
| General & Administrative | $4,063,339 | $1,338,811 |
| Cash and Cash Equivalents (End of Period) | $9,719,310 | $66,533 |
| Working Capital | $9,487,137 | $(1,201,680) |
| Total Assets | $13,034,404 | $3,558,509 |
| Total Liabilities | $2,613,629 | $3,942,828 |
Note: The company is pre-revenue. Operating costs are significantly offset by government and private grants (approx. $2.33M in 2024 and $2.95M in 2023).
Material Changes vs. Prior Period
- Liquidity Surge: Cash and cash equivalents increased by $9.65 million (14,508%) due to the November 2024 IPO, which generated net proceeds of approximately $15.2 million.
- Expense Growth: Total operating costs increased by 217.9% year-over-year. General and Administrative costs rose 203.5% primarily due to IPO-related professional fees and increased compensation. R&D costs (net of grants) increased 254.3% due to higher salaries and lab expenses.
- Debt Reduction: The company repaid approximately $4.24 million in related-party loans to MDB Capital Holdings, LLC using IPO proceeds. The SAFE liability of $1 million was converted to common stock.
- Equity Position: Total stockholders' equity shifted from a deficit of $(384,319) in 2023 to a positive balance of $10.42 million in 2024, driven by the IPO and stock-based compensation.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: The company plans to use IPO proceeds for R&D, staffing, production expansion, and working capital. The commercialization strategy focuses on "nutraceuticals-with-pharmaceutical-potential" to minimize risk, with a secondary focus on isobutanol for Sustainable Aviation Fuel (SAF) supported by a Department of Defense grant. The company intends to commercialize assets via spin-outs, joint ventures, or licensing deals rather than direct manufacturing.
Going Concern Warning: Despite the recent IPO, the financial statements include a "going concern" footnote. Management states there is substantial doubt about the company's ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status. Continued operations depend on securing additional financing or achieving profitable operations.
Key Risks:
- Technology & Commercialization: No assurance that lab-scale results can be replicated at commercial scale or that products will achieve market acceptance.
- Capital Needs: The company expects to incur operating losses for the foreseeable future and will require additional capital, which may result in dilution.
- Grant Dependency: Historically reliant on government grants (DOE, NIH, DOD). There is no guarantee of future grant funding.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, including inadequate design of policies and testing procedures.
- Regulatory: Products (cannabinoids, biofuels) face complex FDA and EPA regulations.
Investor Verification Checklist
- Grant Sustainability: Verify the status and renewal likelihood of the Department of Defense (DOD) and Department of Energy (DOE) grants, which currently offset a significant portion of R&D costs.
- Commercialization Timeline: Assess the specific milestones for the "nutraceutical" and "isobutanol" programs to determine when revenue recognition might begin.
- Capital Runway: Calculate the burn rate against the $9.7M cash balance to determine the runway before additional financing is required.
- Related Party Transactions: Review the remaining $178,966 payable to MDB Capital Holdings, LLC and the concentration of ownership (MDB Capital holds ~48% of shares).
- Internal Control Remediation: Monitor the company's progress in addressing the material weaknesses in internal controls identified in the 2024 audit.